The effect of anxiety, psychopathological symptoms and personality traits on response to treatment in male patients with anogenital warts: a prospective study.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
18
01
2021
accepted:
13
04
2021
pubmed:
30
4
2021
medline:
25
8
2021
entrez:
29
4
2021
Statut:
ppublish
Résumé
In the era of precision medicine, identification of possible predictive factors of clinical response to treatment is fundamental. This need is particularly strong for anogenital warts (AGW), because there are several treatment modalities with different clearance and recurrence rates. However, data regarding the effect of mental health parameters on response to treatment in patients with AGW are lacking. The purpose of the present study was to evaluate the association between patients' mental health parameters and AGW treatment outcomes. This was a single-centre, prospective study that included newly diagnosed male patients with AGW. At their initial visit, all patients completed the State-Trait Anxiety Inventory (STAI), the Symptom Checklist-90-Revised (SCL-90-R) and the Eysenck Personality Questionnaire (EPQ) questionnaires, which evaluate anxiety, psychopathological manifestations and personality traits, respectively. All patients received cryotherapy until clearance of lesions and were followed up for 18 months for detection of recurrences. The study included 167 male patients. The mean number of days for AGW clearance was 89 ± 65. During the 18-month follow-up, 28% of participants showed a recurrence, after a mean number of 150 ± 132 days. No statistically significant association was detected between questionnaires scores and (a) time needed for AGW clearance, (b) time until 1st recurrence and (c) number of recurrences. If confirmed, our findings indicate that we may not need to modify our AGW treatment plan according to a patient's mental health profile.
Sections du résumé
BACKGROUND
BACKGROUND
In the era of precision medicine, identification of possible predictive factors of clinical response to treatment is fundamental. This need is particularly strong for anogenital warts (AGW), because there are several treatment modalities with different clearance and recurrence rates. However, data regarding the effect of mental health parameters on response to treatment in patients with AGW are lacking.
OBJECTIVES
OBJECTIVE
The purpose of the present study was to evaluate the association between patients' mental health parameters and AGW treatment outcomes.
METHODS
METHODS
This was a single-centre, prospective study that included newly diagnosed male patients with AGW. At their initial visit, all patients completed the State-Trait Anxiety Inventory (STAI), the Symptom Checklist-90-Revised (SCL-90-R) and the Eysenck Personality Questionnaire (EPQ) questionnaires, which evaluate anxiety, psychopathological manifestations and personality traits, respectively. All patients received cryotherapy until clearance of lesions and were followed up for 18 months for detection of recurrences.
RESULTS
RESULTS
The study included 167 male patients. The mean number of days for AGW clearance was 89 ± 65. During the 18-month follow-up, 28% of participants showed a recurrence, after a mean number of 150 ± 132 days. No statistically significant association was detected between questionnaires scores and (a) time needed for AGW clearance, (b) time until 1st recurrence and (c) number of recurrences.
CONCLUSION
CONCLUSIONS
If confirmed, our findings indicate that we may not need to modify our AGW treatment plan according to a patient's mental health profile.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1859-1864Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Munoz N, Castellsague X, de Gonzalez AB et al. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 1: S1-S10.
Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infec Dis 2013; 13: 39.
Blomberg M, Dehlendorff C, Kjaer SK. Risk of CIN2+ following a diagnosis of genital warts: a nationwide cohort study. Sex Transm Infect 2019; 95: 614-618.
Kristiansen S, Svensson Å, Drevin L et al. Risk factors for penile intraepithelial neoplasia: a population-based register study in Sweden, 2000-2012. Acta Dermato Venereol 2019; 99: 315-320.
Cho CY, Lo YC, Hung MC et al. Risk of cancer in patients with genital warts: A nationwide, population-based cohort study in Taiwan. PLoS One 2017; 12: e0183183.
O'Mahony C, Gomberg M, Skerlev M et al. Position statement for the diagnosis and management of anogenital warts. J Eur Acad Dermatol Venereol 2019; 33: 1006-1019.
Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2020; 34: 1644-1653.
Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005; 23: 1107-1122.
Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004; 15: 501-508.
Domenech-Vinolas M, Leon-Maldonado L, Ramirez-Palacios P et al. Incidence, psychosocial burden, and economic impact of genital warts in Mexico. Salud Publica Mex 2018; 60: 624-632.
Koupidis SA, Nicolaidou E, Hadjivassiliou M et al. Health related quality of life in patients with anogenital warts. Health Qual Life Outcomes 2011; 9: 67.
Ginieri-Coccossis M, Triantafillou E, Papanikolaou N et al. Quality of life and depression in chronic sexually transmitted infections in UK and Greece: The use of WHOQOL-HIV/STI BREF. Psychiatriki 2018; 29: 209-219.
Drolet M, Brisson M, Maunsell E et al. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis 2011; 38: 949-956.
Esler M. Mental stress and human cardiovascular disease. Neurosci Biobehav Rev 2017; 74: 269-276.
Brown SA, García AA, Brown A et al. Biobehavioral determinants of glycemic control in type 2 diabetes: A systematic review and meta-analysis. Patient Educ Couns 2016; 99: 1558-1567.
Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression and the immune system. Lancet Oncol 2004; 5: 617-625.
Pereira DB, Antoni MH, Danielson A et al. Life stress and cervical squamous intraepithelial lesions in women with human papillomavirus and human immunodeficiency virus. Psychosom Med 2003; 65: 427-434.
Spielberger CD, Gorssuch RL, Lushene PR, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory, Consulting Psychologists Press, Palo Alto, CA, 1983.
Barnes LL, Harp D, Jung WS. Reliability generalization of scores on the Spielberger state-trait anxiety inventory. Educ Psychol Meas 2002; 62: 603-618.
Fountoulakis KN, Papadopoulou M, Kleanthous S et al. Reliability and psychometric properties of the Greek translation of the State-Trait Anxiety Inventory form Y: preliminary data. Ann Gen Psychiatry 2006; 5: 2.
Derogatis LR. Symptom Checklist-90-Revised (SCL-90-R), NCS Pearson, Lyndhurst, NJ, 1979.
Donias S, Karastergiou A, Manos N. Standardization of the symptom checklist-90-R rating scale in a Greek population. Psychiatriki 1991; 2: 42-48.
Eysenck HJ, Eysenck SBG. Manual of the Eysenck Personality Questionnaire, Hodder & Stoughton, London, 1975.
Demitriou EC. Το ερωτηματολόγιο προσωπικότητας EPQ (Eysenck Personality Questionnaire): Στάθμιση στον ελληνικό πληθυσμό, ενήλικο και παιδικό. [The Eysenck Personality Questionnaire (EPQ): The validity of the Greek adult and junior version]. Εγκέφαλος 1986; 23: 41-54.
Chikandiwa A, Pisa PT, Muller EE et al. Incidence, persistence, clearance, and correlates of genital human papillomavirus infection and anogenital warts in a cohort of men living with human immunodeficiency virus in South Africa. Sex Trans Dis 2019; 46: 347-353.
Kaderli R, Schnüriger B, Brügger LE. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis 2014; 29: 899-908.
Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. Genitourin Med 1991; 67: 297-302.
Pontini P, Mastorino L, Gaspari V et al. A multicentre, randomised clinical trial to compare a topical nitrizinc® complex solution versus cryotherapy for the treatment of anogenital warts. Dermatol Ther (Heidelb) 2020; 10: 1063-1073.
Robson C. Real World Research: A Resource for Social Scientists and Practitioner-Researchers, 2nd edn, Blackwell, Malden, MA, 2002.